You Position: Home > Paper

Efficacy of fenofibrate chewable tablets in the treatment of hyperlipidemia

( views:324, downloads:4 )
Author:
No author available
Journal Title:
CHINA MEDICINE
Issue:
6
DOI:
10.3760/cma.j.issn.1673-4777.2009.06.004
Key Word:
高脂血症;非诺贝特;剂型改进;Hyperlipidemia;Fenofibrate;Dosage form improving

Abstract: Objective To evaluate the efficacy and safety of fenofibrate chewable tablets for hyperlipidemic. Methods One hundred patients with serum triglyceride equal to or above 2.26 mmol/L were included. Patients were randomized to fenofibrate chewable tablets (200 mg once a day)group and fenofibrate capsules(200 mg once a day) group for 8 weeks. Results At 8 weeks, administration of two dosage forms of fenofibrate all reduced serum triglycerides (P<0.01) and evoked a significant increase in serum high-density lipoprotein (HDL) cholesterol levels(P<0.01). Median decrease of serum triglycerides was 44.88% and 45.11% in fenofibrate chewable tablets group and fenofibrate capsules group respectively. Mean increase of serum HDL-C holesterol in both groups was 16.51% and 13.35%, respectively. Curative effect of the hyperlipidemia in the fenofibrate chewable tablets group was 84.1% and 86.7% in fenofibrate capsules group. Conclusion Fenofibrate chewable tablets with 200 rag/day showes significant lipid-modifying properties. Efficacy of fenofibrate chewable tablets for treatment of hyperlipidemia has the same effect as fenofibrate capsules.

WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn